confidential - icstipe : panera biotec pvt ltd nvi: netherlands vaccin institut now called as...
TRANSCRIPT
Confidential 1
Confidential
Corporate Overview
Global Footprint
Innovation Infrastructure
Vaccines
Key Business Highlights
Portfolio & Pipeline
Manufacturing Infrastructure for Vaccines, Biosimilars & mAbs
Pharmaceuticals
Key Business Highlights
NCEs
NDDS & Generic Products
Manufacturing Infrastructure (Pharma)
Pipeline Overview
Collaborations
Panacea Bioec in the region
Barriers for doing business
Some suggestions 2
Contents
Confidential
• Pharmaceuticals
• Vaccines
• Biotherapeutics (Biosimilars, mAbs & Peptides) Business Lines
• 2nd Largest Vaccine Producer in India
• Ranked 48th amongst Pharmaceutical Companies in India (ORG-IMS, 2012) Ranking
• Four Research & Development Centers
• Established Sales & Distribution Network in India, 50 branded products
• Direct presence in Germany for specialty hospital products segment
• Presence in 55 ROW and Emerging Markets
• cGMP Manufacturing Facilities
Infrastructure
• 3,800 Human Resource
• 275 in R&D
• 1,200 in Sales and Marketing Manpower
3
Corporate Overview
Confidential
Serbia Bosnia
Germany
Kazakhstan
Belarus
Ukraine
Russia
Syria
Vietnam Thailand
Sri-lanka
Kenya
US
Australia
New Zealand
Philippines
Myanmar
Uganda Nigeria
Tanzania
Mongolia
Cambodia
Singapore
Hong Kong Algeria
Morocco
India
Brazil
Switzerland
Turkey
4
Global Footprint
Confidential 5
Drug Discovery: Small Molecules • Target identification to development of pre-
clinical candidate • Focus areas : Metabolic disorders, Anti-
infectives, CNS
Laksh, Mohali OneStream, New Delhi
Drug Discovery: Novel Biologicals • Target identification to development of pre-
clinical candidate • Focus areas for Novel Peptides: Metabolic
Disorders • Vaccines & Biosimilars
GRAND, Navi Mumbai Sampann, Lalru
NDDS Product Development • Platform NDDS technologies :
Nanoparticles, Liposomes, Micro-particles, Depot Injections, SPORT, Oral films etc.
• High barrier to entry generics
Difficult to Develop Products • High barrier to entry generics • NDDS technologies: Depot Injections, Oral
modified release, SMEDDS in Softgels, MD tablets, Critical dose drugs
• Vaccine Formulation & Bio-therapeutics Development
Innovation Infrastructure
Confidential 6
Vaccines
Confidential 7
• Established presence of over 25 years vaccines
• Reliable partner to WHO, UNICEF: has been largest supplier of vaccines to UNICEF from
India
• First Indian Company to launch innovative branded combination vaccine – Easyfive
(DTP/Hep B/Hib) & other combination vaccines (Easyfour, Ecovac)
• One of the 3 Companies chosen by Govt. of India to develop Flu vaccine (Pandemic Flu)
Vaccine Business – Key Highlights
Confidential
CONFIDENTIAL
• Easyfive (DTwPPTB-HepBPE-Hib-CRM NVD)
• Easyfour (DTwPPTB-Hib-CRMNVD)
• Novohib (HibPE-TTPTB)
• Polprotec (IPVNVI)
• Enivac HB (Hep BPE)
• Ecovac - 4 (DTwPPTB-HepBPE)
• Primopol (tOPVPTB)
• mOPV 1 SP, PTB
• bOPV (type 1 & 3) sp,PTB
# Combination vaccines in Green
• PTB - PT BioFarma • SP - Sanofi Pasture • PE - PanEra Biotec Pvt Ltd • NVD - Novartis Vaccines and Diagnostics • NVI - Netherlands Vaccin Institut
Marketed Vaccine Products
29
Expertise in Combination Vaccines
Confidential
CONFIDENTIAL
• Easyfour-Pol (DTwPPE-Hib-TTPE-- IPVNVI)
• Easysix (DTwPPE-HepBPE-Hib-TTPE- IPVNVI)
• Hapy3 (DTaPPE)
• Hapyfive (DTaPPE-Hib-TTPE- IPVNVI)
• Hapysix (DTaPPE-Hib-TTPE-HepBPE- IPVNVI)
• Dengue (Chimeric Recombinant Tetravalent )
• Japanese Encephalitis (Inactivated cell culture based viral vaccine)
• Pneumococcal Conjugate CRM (10v Phase I;
• 15v conjugate
• Universal Flu (Recombinant viral vectored)
• Seasonal Flu (Quadrivalent seasonal Vaccine)
• Meningococcal (Tetravalent conjugate vaccine
PE : PanEra Biotec Pvt Ltd NVI: Netherlands Vaccin Institut now called as Bilthoven Biologicals
9
Vaccine Pipeline
Confidential 10
Manufacturing Infrastructure Vaccines & Biosimilars
Confidential 11
Mammalian Cell Culture Products • MAbs • Biosimilars
• Low pressure Chromatography
Gel Filtration Chromatography
Ion exchange chromatography
• Tangential flow filtration (TFF)
Concentration / Diafiltration
• HPLC
• Centrifugation
• Sterile filtration
• Purification High Pressure Chromatography Medium Pressure Chromatography
System
• Fermentation Capacity at
Production Level
Pre inoculum preparation - 1 x 5 L
Inoculum Preparation - 1 x 50 L
Production fermentation - 2 x 500 L
Harvesting - Microfiltration (TFF)
Bio-therapeutics: Manufacturing Capabilities
Confidential 12
Indigenous & fully integrated bulk antigen manufacturing facilities
Location Bulk Antigen Facilities Built Up Area
Recombinant Vaccines
Bacterial Vaccines
Tetanus Vaccine
Cell Culture Vaccines
Lalru
~ 40,000 sq. ft
~ 18,000 sq. ft
~ 20,000 sq. ft
~ 30,000 sq. ft
(US-FDA / UK-MHRA compliant)
• Licensed Bulk Antigens – Diphtheria Toxoid • Tetanus Toxoid • Whole cell / acellular Pertussis Haemophilus influenzae type b conjugate • Recombinant Hepatitis B Inactivated H1N1 split viron influenza vaccine bulk (egg based technology)
• Facility has provision for production of Bulk Antigens which are under development Vaccines : Dengue Vaccine, Japanese Encephalitis, Sabin IPV, egg based seasonal flu
vaccine, Yellow Fever vaccine Bio therapeutics : Viral proteins, non-viral recombinant bio molecules on cell culture in
both conventional & disposable formats
Vaccine - Manufacturing Capabilities
Confidential 13
Formulation Capacity of 1.6 billion doses p.a. (Includes Vials & PFS)
Location Formulation Facilities Capacities (mn doses/yr ) Built Up Area
Delhi 1 line for Oral vaccines 800 ~ 50,000 sq ft
Baddi 3 lines. 2 for Vials , 1 for PFS PFS-16
Single dose -39 20 Dose -800
~ 129,167 sq ft
Facility Location: Baddi, Himachal Pradesh
Vaccine - Manufacturing Capabilities
Confidential 14
Key Business Highlights Pharma
Confidential
Market Key Achievements Pipeline
ROW
Latin America: Brazil, Other Latin America
CIS: Russia, Serbia, Srspska & Bosnia, Kazakhstan, Ukraine, Uzbekistan, Belarus
Asia: Vietnam , Cambodia, Myanmar, Mongolia, Philippines, Sri Lanka
Middle East: Syria, Jordan
Africa: Kenya, Uganda, Tanzania, Nigeria
• Commercialized over 50 brands in more than
20 countries
• Major brands: Alhpadol, Dolzero, Fosbait, Glizid
Range, Livoluk, Mycept, Nimulid Range, Ocimix,
Pangraf, Panimun, Sitcom, Thank OD, Toff MD & Toff
Plus
• 20 Branded Generics
• 3 NDDS
Pipeline Products available for out licensing:
• 40 Branded Generics
• 7 NDDS
TACROFORT
Pharmaceutical Business – ROW
Confidential 16
Major Therapeutic Areas
Key Brands Key Achievements Future Pipeline
Organ
Transplantation,
Renal Disease
Pangraf, Panimun Bioral, Mycept, Fosbait , Epotrust
• Leadership in organ transplant market with 30% market share in respective segment
• Pangraf and Fosbait ranked 1st in respective segment
• Panimum Bioral and Mycept ranked 2nd in respective segment
• 2 NDDS products • 3 Branded generic products
Oncology PacliALL
• 1st to introduce Albumin bound formulation of Paclitaxel in India
• PacliALL ranked 2nd in the respective segment
• 1 Nanoparticle based product • 2 Liposomal products • 2 Depot injections • 7 Branded generic products
Diabetes ,
Cardiovascular
Glizid , Glizid –M, Glizid MR, Glizid Total
• Glizid ranked 1st among Gliclazide and Gliclazide combination market with ~ 20% market share
• 1 NDDS product • 4 Branded generic products
Pain
Management
Willgo, Nimulid MD, Nimulid SP, Nimulid MR
• Nimulid Group ranked Number 3 amongst the Nimesulide and Nimesulide combinations market
• 1 NDDS product • 1 Branded generic product
Pharmaceutical Business – India
Confidential 17
Pharma Formulation Facility, Baddi
• State-of-the-art cGMP facility approved by US FDA, EU agencies, ANVISA, and TGA amongst others
• 161 Product Approvals from 14 countries
• Maintain high standards of manufacturing by using state of art GMP compliant machines
Production Lines Annual Capacity (in Millions)
Anticancer (Cytotoxic Products)
Liquid and Lyophilized Injectables
1.2
Tablets & Capsules 50
Other Dosage Forms
Tablets 3,000
Hard Gelatin Caps 650
Soft Gelatin Caps 150
Ointments & Gels 42
Liquid Orals 24
Dietary Supplements 300
Pharmaceutical - Manufacturing Capabilities
Confidential 18
Difficult to
develop
Generics
NCE Biosimilars,
Peptides,
Vaccines
Pipeline
Generics
NCE & Peptides
• 4 Best in Class NCE
• 1 Atypical NCE
• 2 Novel Peptides
Biosimilars, Peptides, Vaccines • 4 Biosimilars in
development • 4 Peptides in
development • 10 Innovative
vaccines in development
ICH Region:
• 1 Generic Launched in US
• 2 ANDAs under review in US
• 2 MAA granted in Europe
• 29 ANDAs in development
NDDS
NDDS
• 7 best in class NDDS products in development (Scientific advice from US / European agencies has been taken for 5 products)
Pipeline Overview
Confidential 19
Marketing Partnership in US
Major Collaborations
RIVM, Netherlands
Confidential
PBL
20
Panacea Biotec in the region
• With Binnopharm
• Intially HiB Vaccine, other pipeline products in due course
RUSSIA
• Global Alliance with Osmotica
• Advanced R&D and product marketing
HUNGARY
• With Alymore Corporation
• Products Easyfive, Polprotec KAZAKHSTAN
• With Uzbiopharma
• Products Easyfive, Polprotec UZBEKISTAN
Confidential
s
21
Barriers for doing business
Secured Banking
Language
Monopolistic Market
domination
High Entry
Barriers
Transparency
High Cost of
Operation
Confidential 22
Some suggestions
Reduce registration timelines
Single Window agency : for enhanced interface with Local companies & fast track approval
Set clear SOPS for the Bio technology Industry as well as allied products : Local initiative
National level support to Local manufacturing companies – hence, increased need to collaborate for “localising” the operations
Partnering in Govt programmes – Pharma 2020
Confidential
For more information, please visit our website at
www.panaceabiotec.com
Dr. Goutam Ghosh
Panacea Biotec Ltd. B-1 Extn./G-3, Mohan Co-op. Indl. Estate, Mathura Road,
New Delhi-110 044, INDIA
Phone : +91 11 4167 9012
Fax : +91 11 4167 9068
Email : [email protected]
23